Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 13/20 | 0.68 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15224138 | 1.00 | EPHX1 (0.68) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL19420509 | 0.87 | EPHX1 (0.86) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL9750349 | 0.87 | EPHX1 (0.86) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL4136149 | 0.84 | EPHX2 (0.76) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL8428972 | 0.82 | EPHX1 (0.68) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL1193592 | 0.82 | EPHX1 (0.97) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL5020902 | 0.82 | EPHX1 (0.90) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL12900728 | 0.81 | EPHX1 (0.68) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL1064217 | 0.81 | EPHX1 (0.77) | EPHX1EPHX2 | |
| SCHEMBL1065092 | 0.81 | EPHX2 (1.00) | EPHX1EPHX2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2439202-B1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | SALVAT LAB SA (ES) | 2016-04-20 | — | — | EP | disclosed |
| US-8822452-B2 | Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 | LABORATORIOS SALVAT, S.A. (ES) | 2014-09-02 | — | — | US | disclosed |
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-11-14 | — | — | US | disclosed |
| US-8524894-B2 | Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-09-03 | — | — | US | disclosed |
| EP-1829876-A1 | NITROGENEOUS TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | EPHX1 227/4885EPHX2 1149/4885KDM4E 4105/4885 |
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | MYO1B, CHRM1, MYL12A | EPHX1 4424/4885EPHX2 4385/4885KDM4E 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.